Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the efficacy and safety of co-administrated Rosuvastatin/Ezetimibe and Telmisartan in patients with primary hypercholesterolemia and essential hypertension.
This trial is a phase 3 study to evaluate efficacy and safety of co-administrated Rosuvastatin/Ezetimibe and Telmisartan in patients with primary hypercholesterolemia and essential hypertension.
In "Rosuvastatin/Ezetimibe+Telmisartan" treatment group, 60 subjects will be assigned and the subjects administer "Rosuvastatin/Ezetimibe+Telmisartan" for 8 weeks.
In "Rosuvastatin/Ezetimibe" treatment group, 60 subjects will be assigned and the subjects administer "Rosuvastatin/Ezetimibe" for 8 weeks.
In "Telmisartan" treatment group, 60 subjects will be assigned and the subjects administer "Telmisartan" for 8 weeks.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ezetimibe/Rosuvastatin and Telmisartan | Experimental | 60 subjects will be assigned and the subjects will be administered "Ezetimibe/Rosuvastatin and Telmisartan" for 8 weeks. |
|
| Ezetimibe/Rosuvastatin | Active Comparator | 60 subjects will be assigned and the subjects will be administered "Ezetimibe/Rosuvastatin" for 8 weeks. |
|
| Telmisartan | Active Comparator | 60 subjects will be assigned and the subjects will be administered "Telmisartan" for 8 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ezetimibe/Rosuvastatin | Drug | PO, Once daily(QD), 8weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Low density lipoprotein cholesterol (LDL-C) | LDL-C change at Week 8 compared to Baseline | Baseline, Week 8 |
| Mean sitting systolic blood pressure (MSSBP) | MSSBP change at Week 8 compared to Baseline | Baseline, Week 8 |
| Measure | Description | Time Frame |
|---|---|---|
| Mean sitting systolic blood pressure (MSSBP) | MSSBP change at Week 4 compared to Baseline | Baseline, Week 4 |
| Low density lipoprotein cholesterol (LDL-C) | LDL-C change at Week 4 compared to Baseline |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Hyo Soo Kim, M.D., Ph.D | Seoul National University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Seoul National University Hospital | Seoul | 03080 | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006937 | Hypercholesterolemia |
| D006973 | Hypertension |
| ID | Term |
|---|---|
| D006949 | Hyperlipidemias |
| D050171 | Dyslipidemias |
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069438 | Ezetimibe |
| D000068718 | Rosuvastatin Calcium |
| D000077333 | Telmisartan |
| ID | Term |
|---|---|
| D001384 | Azetidines |
| D001385 | Azetines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Telmisartan | Drug | PO, Once daily(QD), 8weeks |
|
|
| Baseline, Week 4 |
| Mean sitting diastolic blood pressure (MSDBP) | MSDBP change at Week 4, 8 compared to Baseline | Baseline, Week 4, Week 8 |
| Total Cholesterol (TC) | TC change at Week 4, 8 compared to Baseline | Baseline, Week 4, Week 8 |
| High density lipoprotein cholesterol (HDL-C) | HDL-C change at Week 4, 8 compared to Baseline | Baseline, Week 4, Week 8 |
| Triglyceride (TG) | TG change at Week 4, 8 compared to Baseline | Baseline, Week 4, Week 8 |
| Low density lipoprotein cholesterol/High density lipoprotein cholesterol (LDL-C/HDL-C) | LDL-C/HDL-C change at Week 4, 8 compared to Baseline | Baseline, Week 4, Week 8 |
| Total Cholesterol/High density lipoprotein cholesterol (TC/HDL-C) | TC/HDL-C change at Week 4,8 compared to Baseline | Baseline, Week 4, Week 8 |
| D009750 |
| Nutritional and Metabolic Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D013449 |
| Sulfonamides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D005464 | Fluorobenzenes |
| D006845 | Hydrocarbons, Fluorinated |
| D006846 | Hydrocarbons, Halogenated |
| D006838 | Hydrocarbons |
| D013450 | Sulfones |
| D013457 | Sulfur Compounds |
| D011743 | Pyrimidines |
| D001713 | Biphenyl Compounds |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D001562 | Benzimidazoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |